Date published: 2025-12-21

1-800-457-3801

SCBT Portrait Logo
Seach Input

UBE2Q1 Activators

UBE2Q1 activators are a class of chemical compounds that interact with the ubiquitin-proteasome system (UPS), specifically targeting the E2 enzyme UBE2Q1 to modulate its activity. The activation of UBE2Q1 can be achieved through indirect mechanisms that lead to an increased demand for ubiquitination within the cell. For instance, by inhibiting the proteasome or interfering with deubiquitinating enzymes, a buildup of ubiquitinated proteins occurs. This buildup can trigger a cellular response that involves the upregulation or enhanced activity of ubiquitinating enzymes, including UBE2Q1, which functions to attach ubiquitin to substrate proteins, marking them for degradation or altering their function. The inhibition of upstream enzymes in the ubiquitination pathway, such as E1 enzymes or NEDD8-activating enzymes, also exerts a compensatory response that can include the activation of UBE2Q1. This response is a part of the cell's effort to maintain protein homeostasis, a critical aspect of numerous cellular functions and overall cellular health.

The study of UBE2Q1 activators encompasses a range of molecular strategies that leverage the intrinsic regulatory mechanisms of the UPS. By increasing the cellular levels of ubiquitinated substrates, either through the inhibition of their breakdown or through the suppression of their deubiquitination, these activators create a cellular environment that necessitates the engagement of UBE2Q1. The understanding of such mechanisms has led to insights into how cells maintain the delicate balance of protein synthesis and degradation. It is important to acknowledge that while the activation of UBE2Q1 is linked to the modulation of ubiquitin-dependent processes, the exact cellular pathways that lead to its activation and the full scope of its endogenous substrates remain areas of active investigation. The relationship between UBE2Q1 and the broader UPS underscores the complexity and interconnectivity of cellular regulatory systems, where changes in one component can have wide-reaching effects on the entire proteostasis network.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$132.00
$1064.00
115
(2)

Bortezomib is a boronic acid derivative and a potent proteasome inhibitor. It primarily affects the chymotrypsin-like activity of the proteasome. By preventing the degradation of ubiquitinated substrates, bortezomib could possibly activate UBE2Q1.

MLN 4924

905579-51-3sc-484814
1 mg
$280.00
1
(0)

MLN4924 is a small molecule inhibitor of NEDD8-activating enzyme (NAE). While it targets the neddylation pathway, the inhibition of NAE could possibly activate UBE2Q1 through broader effects on protein turnover and ubiquitination.

Lactacystin

133343-34-7sc-3575
sc-3575A
200 µg
1 mg
$165.00
$575.00
60
(2)

Lactacystin is a natural product that irreversibly inhibits proteasomal activity. Its effect is similar to that of bortezomib and MG132 in that it can increase the load of ubiquitinated proteins, which could possibly activate UBE2Q1.

R-(+)-Etomoxir

124083-20-1sc-208201A
sc-208201
2 mg
5 mg
$245.00
$430.00
(0)

P22077 is a small molecule inhibitor of the deubiquitinating enzymes USP7 and USP47. By modulating the deubiquitination activity, P22077 could possibly activate UBE2Q1.

Thalidomide

50-35-1sc-201445
sc-201445A
100 mg
500 mg
$109.00
$350.00
8
(0)

Thalidomide and its derivatives, such as lenalidomide and pomalidomide, have been shown to affect the ubiquitin-proteasome system. While they primarily target E3 ubiquitin ligases, their broader impact on ubiquitination could possibly activate UBE2Q1.